drugset / Trial / NCT05512416
Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer
Phase 2
Unknown
35 enrolled
The Affiliated Hospital of Qingdao University
Jiangsu HengRui Medicine Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
In this single arm, open label, phase 2 trial, operable patients with stage IIB-III HR+/HER2- breast cancer will be enrolled and receive six cycles of adjuvant dalpiciclib plus letrozole. This study aims to assessed the biological effects and safety of dalpiciclib in combination with letrozole for HR+/HER2- breast cancer in the neoadjuvant setting.
Timeline
- Start
- 2022-08
- Primary completion
- 2023-08
- Completion
- 2024-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalpiciclib | Small molecule | 150 mg | Oral |
| Subject | Letrozole | Other / unclassified | 2.5 mg | Oral |